Furthermore, ex vivo treatment of tumor-infiltrating CD4+ T cells with activin-A bestowed them with robust effector properties which were maintained upon therapeutic transfer in vivo and empowered them to protect against lung cancer progression. This evidence concerns the gene CD4 and neoplasm.